Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

NCT02431767 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

94

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: PENNVAX®-GP HIV-1 DNA vaccine
BIOLOGICAL: Interleukin-12 (IL-12) DNA adjuvant
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)